Lessons from SAVOR and EXAMINE: Some important answers, but many open questions

Journal of Diabetes and its Complications

Volumn 28, Issue 4, 2014, Pages 430-433

  Schernthaner, Guntram ^a   Sattar, Naveed ^b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; PIPERIDINE DERIVATIVE; URACIL;

ACUTE PANCREATITIS; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC PANCREATITIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING CESSATION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; EVIDENCE BASED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADAMANTANE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URACIL;

EID: 84903270722     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.02.011     Document Type: Editorial

References (29)

1. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes The New England Journal of Medicine 358 2008 2545 2559
2. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes The New England Journal of Medicine 358 2008 2560 2572
3. P.C. Butler, M. Elashoff, R. Elashoff, and E.A. Gale A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36 2013 2118 2125
4. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, and I.K. Moules et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
5. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven et al. Glucose control and vascular complications in veterans with type 2 diabetes The New England Journal of Medicine 360 2009 129 139
6. Emerging Risk Factors Collaboration N. Sarwar, P. Gao, S.R. Seshasai, R. Gobin, and S. Kaptoge et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
7. E.W. Gregg, Y.J. Cheng, S. Saydah, C. Cowie, S. Garfield, and L. Geiss et al. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey Diabetes Care 35 2012 1252 1257
8. E.L. Grove, and S. Gregersen Antiplatelet therapy in patients with diabetes mellitus Current Vascular Pharmacology 10 2012 494 505
9. P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, and M. Hanefeld et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
10. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf
11. R. Huxley, A. Ansary-Moghaddam, A. Berrington de Gonzalez, F. Barzi, and M. Woodward Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies British Journal of Cancer 92 2005 2076 2083
12. Janssen Research & Development LLC Advisory committee briefing materials: Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus Endocrinologic and Metabolic Drugs Advisory Committee 2012 1 184
13. M.K. Lau, J.A. Davila, and Y.H. Shaib Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States Pancreas 39 2010 458 462
14. M. Lind, L.A. Garcia-Rodriguez, G.L. Booth, L. Cea-Soriano, B.R. Shah, and G. Ekeroth et al. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population- based study Diabetologia 56 2013 2601 2608 10.1007/s00125-013-3063-1 (A corrected version of the paper is available at:)
15. J. Luo, L. Xiao, C. Wu, Y. Zheng, and N. Zhao The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004-2009 PLoS One 8 10 2013 e76052
16. J. McMurray Vildagliptin shows no adverse effect on ejection fraction in diabetic patients with HF Presented at the Heart Failure Congress 2013, Lisbon, Portugal, May 25-28, 2013 2013 (abstract)
17. M. Monami, B. Ahrén, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and cardiovascular risk a meta-analysis of randomized clinical trials Diabetes, Obesity & Metabolism 15 2013 112 120
18. M.A. Nauck A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks Diabetes Care 36 2013 2126 2132
19. B. Neal, V. Perkovic, D. de Zeeuw, K.W. Mahaffey, G. Fulcher, and P. Stein et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial American Heart Journal 166 2013 217 223
20. ORIGIN Trial Investigators, H.C. Gerstein, J. Bosch, G.R. Dagenais, R. Díaz, and H. Jung et al. Basal insulin and cardiovascular and other outcomes in dysglycemia The New England Journal of Medicine 367 2012 319 328
21. X. Ou, H.A. O'Leary, and H.E. Broxmeyer Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types Blood 122 2013 161 169
22. S.R. Preis, S.J. Hwang, S. Coady, M.J. Pencina, D'Agostino, and P.J. Savage Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 Circulation 119 2009 1728 1735
23. N. Sattar Revisiting the links between glycaemia, diabetes and cardiovascular disease Diabetologia 56 2013 686 695
24. A.J. Scheen Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes Postgraduate Medicine 125 2013 7 20
25. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus The New England Journal of Medicine 369 2013 1317 1326
26. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
27. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes The New England Journal of Medicine 369 2013 1327 1335
28. D. Yadav, and A.B. Lowenfels The epidemiology of pancreatitis and pancreatic cancer Gastroenterology 144 2013 1252 1261
29. L. Yang, Z. He, X. Tang, and J. Liu Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis European Journal of Gastroenterology & Hepatology 25 2013 225 231